SCHEMBL23285686

SCHEMBL23285686

CC(=O)C(=C/C=C(\Cl)c1ccccc1OC(=O)c1ccccc1)C(C)=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 1/20 0.56
KMT2A Q03164 6/20 0.46
MAPT P10636 5/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 5/20 0.46
HSD17B10 Q99714 4/20 0.46
LMNA P02545 3/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
GAA P10253 2/20 0.44
ELANE P08246 1/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 3/20 0.43
MEN1 O00255 2/20 0.43
HSP90AA1 P07900 2/20 0.43
ESR1 P03372 3/20 0.43
ITGB3 P05106 1/20 0.43
ITGA2B P08514 1/20 0.43
HMGB1 P09429 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26092280 1.00 SLC6A3 (0.56) SLC6A3KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL23276223 0.82 SLC6A3 (0.58) SLC6A3KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL23275580 0.82 SLC6A3 (0.58) SLC6A3KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL23285692 0.82 SLC6A3 (0.57) SLC6A3KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL26090915 0.81 KMT2A (0.52) KMT2AMAPTSMN1; SMN2KDM4ELMNA
SCHEMBL26490229 0.81 KMT2A (0.52) KMT2AMAPTSMN1; SMN2KDM4ELMNA
SCHEMBL26490205 0.80 SLC6A3 (0.51) SLC6A3KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL26091761 0.80 SLC6A3 (0.51) SLC6A3KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL23275558 0.79 MAPT (0.47) KMT2AMAPTSMN1; SMN2KDM4ELMNA
SCHEMBL11346276 0.77 SLC6A3 (0.68) SLC6A3KMT2AMAPTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230130823-A1 PROCESS FOR THE PRODUCTION OF ANTITUMOUR PHARMACEUTICAL COMPOSITIONS USING PUSH-PULL BUTADIENES, COMPOUNDS AND USES THEREOF ANHANGUERA EDUCACIONAL PARTICIPAÇÕES S/A (BR) 2023-04-27 US disclosed
US-20230130823-A1 PROCESS FOR THE PRODUCTION OF ANTITUMOUR PHARMACEUTICAL COMPOSITIONS USING PUSH-PULL BUTADIENES, COMPOUNDS AND USES THEREOF ANHANGUERA EDUCACIONAL PARTICIPAÇÕES S/A (BR) 2023-04-27 US disclosed
WO-2021077194-A1 PROCESS FOR THE PRODUCTION OF ANTITUMOUR PHARMACEUTICAL COMPOSITIONS USING PUSH-PULL BUTADIENES, COMPOUNDS AND USES THEREOF ANHANGUERA EDUCACIONAL PARTICIPAÇÕES S/A (BR) 2021-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230130823-A1 PROCESS FOR THE PRODUCTION OF ANTITUMOUR PHARMACEUTICAL COMPOSITIONS USING PUSH-PULL BUTADIENES, COMPOUNDS AND USES THEREOF BAD, BAX, PDCD4 SLC6A3 3688/4885KMT2A 4589/4885MAPT 3567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.